Company: NIVFW
Filing Date: 2025-03-07
Form Type: F-1
Source: 0001213900-25-021404
Chunk: 143

Company: NewGenIvf Group Ltd
Filing Date: 2025-03-07
Form: F-1
Chunk 143
---
 services and other companies may introduce similar fertility services as NewGenIvf’s, NewGenIvf may become subject to additional competition. Facilities As of December 31, 2023, in addition to its clinics, NewGenIvf leased one property in Hong Kong with an aggregate square footage of approximately 8,000 for its administration support offices. NewGenIvf also operates its medical facilities as described above in “— Network of Facilities” above. NewGenIvf believes that its existing facilities are suitable and adequate to meet its current needs. 103 SELLING SECURITYHOLDER This prospectus relates to the possible resale from time to time by the Selling Securityholders of up to 9,275,000 Class A Ordinary Shares, which includes (i) 125,000 Class A Ordinary Shares issued to Genetics and IVF Institute pursuant to the MicroSort Purchase Agreement; (ii) 150,000 Class A Ordinary Shares issued to ASPAC pursuant to the Consulting Services Agreement; (iii) 6,000,000 Class A Ordinary Shares issuable upon the conversion of (a) the Remaining Additional Notes (as defined below), (b) the senior convertible notes exchanged on August 8, 2024 (“Exchange Notes”), (c) the exercise of Series A warrants to purchase Class A Ordinary Shares (the “Series A Warrants”), (d) the exercise of Series B warrants to purchase Class A Ordinary Shares (the “Series B Warrants”), (e) the exercise of Series C warrants to purchase Class A Ordinary Shares (the “Exchange Warrants” and together with the Series A Warrants and the Series B Warrants, the “Warrants”); and (iv) 3,000,000 Class A Ordinary Shares issuable by the Company to White Lion Capital, LLC (“White Lion”) in connection with the Common Stock Purchase Agreement dated as of November 21, 2024, by and between the Company and White Lion (the “White Lion Purchase Agreement”). We are registering the Resale Shares to satisfy certain registration rights that we have granted to the Selling Securityholders. The Selling Securityholders may from time to time offer and sell any or all of the securities set forth below pursuant to this prospectus. When we refer to the “Selling Securityholders” in this prospectus, we mean the persons listed in the tables below, and the pledgees, donees, transferees, assignees, successors and others who later come to hold any of the Selling Securityholders’ interest in our securities